Can Amgen Stop The Bleeding As FDA Presses For A Low-Dose Aranesp Trial?
This article was originally published in The Pink Sheet Daily
Executive Summary
CardioRenal Advisory Committee will discuss whether there should be a trial testing lower dosing limits in CKD patients. With sales declines a forgone conclusion regardless, Amgen hopes to avoid the expense of a complex study.